Entrada Therapeutics (TRDA) Other Non Operating Income (2020 - 2026)

Entrada Therapeutics' Other Non Operating Income history runs 7 years deep, the most recent figure standing at $2.6 million for Q1 2026.

• In Q1 2026, Other Non Operating Income fell 40.91% year-over-year to $2.6 million; the TTM figure through Mar 2026 stood at $13.3 million (down 32.72% YoY), while the FY2025 annual figure was $15.1 million, down 22.6% from the prior year.
• Other Non Operating Income for Q1 2026 stood at $2.6 million, down from $3.1 million in the prior quarter.
• The five-year high for Other Non Operating Income was $5.8 million in Q3 2024, with the low at $403000.0 in Q2 2022.
• The 5-year median for Other Non Operating Income is $3.9 million (2025), against an average of $3.2 million.
• The sharpest annual moves came in 2022 and 2026: Other Non Operating Income surged 7207.69% in 2022, then slumped 40.91% in 2026.
• Entrada Therapeutics' Other Non Operating Income stood at $950000.0 in 2022, then soared by 351.79% to $4.3 million in 2023, then gained by 19.48% to $5.1 million in 2024, then sank by 38.85% to $3.1 million in 2025, then declined by 16.33% to $2.6 million in 2026.
• Business Quant data shows TRDA's Other Non Operating Income at $2.6 million in Q1 2026, $3.1 million in Q4 2025, and $3.6 million in Q3 2025.